Rahmer Peter's Form 4 filing
Relay Therapeutics, Inc. (RLAY) · filed Jun 5, 2024
- Accession no.
- 0000950170-24-069553
- Filed
- Jun 5, 2024
- Trade date
- Jun 3-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $542.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rahmer PeterCIK 0001959229 | Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | Common Stock | SSaleDisposed | −19,864 | $6.47 | −$128,520.08 | 493,470 | Direct | |
| Jun 4, 2024 | Common Stock | SSaleDisposed | −40,595 | $6.64F4 | −$269,550.8 | 452,875 | Direct | |
| Jun 5, 2024 | Common Stock | SSaleDisposed | −20,450 | $7.06F5 | −$144,377 | 432,425 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
This transaction was executed in multiple trades at prices ranging from $6.56 to $6.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $6.97 to $7.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Corporate Development Officer